Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01244061 · ClinicalTrials.gov registry record · Phase 4

A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

A Phase 4 study of Smoking Cessation, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
498
Enrollment target
20
Study locations

NCT01244061 is a Phase 4 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 498 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01244061, a Phase 4 study of Smoking Cessation, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
498 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).

Conditions Studied

Smoking Cessation

Interventions

  • DRUG Placebo
  • DRUG Varenicline

Study Locations (20)

Other

  • Universitair Ziekenhuis Antwerpen, Afdeling Pneumologie - Edegem
  • Universitaire Ziekenhuizen Leuven/Pneumologie - Leuven
  • Centre Hospitalier Universitaire de Liege - Liège
  • Cliniques Universitaires U.C.L. de Mont-Godinne/Laboratoire - Yvoir

California

  • Ronald Reagan University of California Los Angeles Medical Center - Los Angeles
  • University of California Los Angeles David Geffen School of Medicine - Los Angeles

Queensland

  • Royal Brisbane and Women's Hospital - Herston
  • AusTrials Australia - Sherwood

Florida

  • Avail Clinical Research, LLC - DeLand

Kentucky

  • Central Kentucky Research Associates, Inc. - Lexington

Maryland

  • The University of Maryland - College Park

Missouri

  • The Center for Pharmaceutical Research, PC - Kansas City

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 498 participants
Start Date 2010-12
Est. Completion 2012-11
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01244061

The ClinicalTrials.gov registry entry for NCT01244061 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01244061 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Queensland.

Frequently Asked Questions

What is clinical trial NCT01244061 about?

NCT01244061 is a clinical study titled "A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider". The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks afte...

What is the current status of trial NCT01244061?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 498 participants. The study started on 2010-12. Estimated completion is 2012-11.

What conditions does trial NCT01244061 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT01244061?

The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).

Who is sponsoring clinical trial NCT01244061?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01244061 being conducted?

This trial has 20 study locations across California, Florida, Kentucky, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Smoking Cessation

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.